Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I ; volume:12 ; number:1 ; day:17 ; month:9 ; year:2012 ; pages:1-8 ; date:12.2012
BMC cancer ; 12, Heft 1 (17.9.2012), 1-8, 12.2012
- Creator
- Contributor
-
Metodieva, Anna
Badura, Susanne
Khateb, Mamduh
Ruimi, Nili
Najajreh, Yousef
Ottmann, Oliver Gerhard
Mahajna, Jamal
Ruthardt, Martin
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-411
- URN
-
urn:nbn:de:1111-20160304128
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mian, Afsar Ali
- Metodieva, Anna
- Badura, Susanne
- Khateb, Mamduh
- Ruimi, Nili
- Najajreh, Yousef
- Ottmann, Oliver Gerhard
- Mahajna, Jamal
- Ruthardt, Martin
- SpringerLink (Online service)
Other Objects (12)
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia
Expressionshemmung des humanen Onkogens Bcr-Abl durch RNA-Interferenz
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia
Expressionshemmung des humanen Onkogens Bcr-Abl durch RNA-Interferenz
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia